Francesco Amorelli

MD - Radiation Oncologist ☢️ / PhD Student🧑🏻‍🎓 Passionate about nutrition and fitness in free time🏋🏻‍♂️

[Francesco Amorelli @fgamorelli]

We presented at ESTRO 25 our prospective phase II trial evaluated the feasibility and efficacy of IORT with a dose of 20 Gy following surgical resection of brain metastases.

✅In the first 12 patients treated all cases, achieving a 91.7% LC rate with no cases of radionecrosis.

[Francesco Amorelli @fgamorelli]

PLATO platform presented at ESTRO 26: risk-adapted radiotherapy dosing in anal cancer appears feasible, with most quality-of-life impairments improving by 6 months, while ongoing follow-up will help better define long-term toxicity and patient-reported outcomes.

[Francesco Amorelli @fgamorelli]

Promising early toxicity results from the NODES trial presented at ESTRO 26: 5-fraction pelvic RT appears feasible, with only a slight transient increase in acute GI toxicity and no increase in GU side effects. Looking forward to long-term outcomes!!

[Francesco Amorelli @fgamorelli]

New Standards in Cervical Cancer Care NCCN 2026

[Francesco Amorelli @fgamorelli]

We’re kicking off the 2026 scientific season 🧬

[Francesco Amorelli @fgamorelli]

Empieza la elección MIR
Si buscas una especialidad con lo mejor de la clínica, intervencionismo y en constante evolución la oncología radioterapica es para ti 🧬☢️ #EligeOR #MIR2025

[SEOR.es @SEOR_ESP]

¿Buscas una especialidad con innovación, contacto clínico y un alto impacto en la vida de los pacientes? La #OncologíaRadioterápica lo tiene TODO: tecnología, investigación, clínica y quirófano. ¡Descúbrela!
#EligeOR #MIR2025

[Jeff Ryckman @jryckman3]

EMBRACE II: New standard of care for locally advanced cervical cancer!

📌 Advanced RT technology.
📌 Image-guided adaptive brachytherapy.
📌 Limited overall treatment time.
📌 Excellent disease control and overall survival.
📌 Low late severe morbidity.

#ESTRO2025

[Milos Grujic @grujicmilos10]

10-Year Update from the FLAME Trial at #ESTRO25
🔥 Isotoxic focal boost improves long-term outcomes in intermediate/high-risk #ProstateCancer.
📈 10-year results:

bDFS: 86% vs. 71% (HR = 0.40; p<0.0001)
DFS: 81% vs. 66% (p<0.001)
DMFS: 87% vs. 82% (ns)
OS: No significant difference

💡 Dose-response observed even in DMFS
Should focal boosts become standard?
@ESTRO_RT
#RadOnc #FLAMEtrial #Oncology #RadiationTherapy #UroOncology

[Abrahams Ocanto @abraocantoMD]

Phase II trial IORT post-resection of brain metastases shows promising local control with 20 Gy. Among 12 patients, recurrence was 8.3% (subtotal resection), no radionecrosis observed. IORT appears effective and safe with favorable toxicity

@fgamorelli #ESTRO25

[Francesco Amorelli @fgamorelli]

Today we will present the preliminary results of the study IORT after surgical resection of brain metastases: feasibility and efficacy NCT04847284 #ESTRO25 @palmiforo

[Francesco Amorelli @fgamorelli]

Ready for ESTRO 2025 !! ✅

[Francesco Amorelli @fgamorelli]

PSMA PET/CT is a Game-Changer in Recurrent Prostate Cancer

In patients with biochemical recurrence after radical prostatectomy, our study found that PSMA PET/CT with 18F-DCFPyL detected lesions in 53% of cases—even at low PSA levels ✅✅

https://t.co/1MILoXPjfF

[Abrahams Ocanto @abraocantoMD]

📄 New article

📊 In post-prostatectomy BCR with PSA 0.2-2.0 ng/mL and negative conventional studies, PET/CT with 18F-DCFPyL-PSMA detected disease in 53% of cases.

🧭 Implied therapeutic change in 84.4%

Congrats to all authors 👏 👏

https://t.co/HU2Ofr2hWi

[Francesco Amorelli @fgamorelli]

Our latest publication on 18F-DFCPyL PSMA PET/CT as a key diagnostic tool in decision making for patients with biochemical recurrence of prostate cancer ☢️🏥 ⁦ https://t.co/XvmpCezH41

[Francesco Amorelli @fgamorelli]

@palmiforo @hospitaldelmar @SEOR_ESP

[Francesco Amorelli @fgamorelli]

3/3 see u in @ESTRO_RT 2025 💪🏻

[Hospital del Mar @hospitaldelmar]

El Servicio de #OncologíaRadioterápica incorpora un nuevo #software para mejorar el tratamiento de pacientes con #metástasis cerebral

Es pionero en Cataluña en su incorporación. Permite incrementar la precisión del cálculo de la dosis de #radioterapia

https://t.co/oLNvnmvJm9

[Núria Rodg de Dios @nuria_dios]

Cardiac substructure delineation in radiation therapy – A state‐of‐the‐art review - Finnegan - Journal of Medical Imaging and Radiation Oncology - Wiley Online Library https://t.co/1cClNzQMoI

[Francesco Amorelli @fgamorelli]

Después de 24h de guardia en la planta de oncohemato mi descanso es una antigua habitación de pacientes, compartiendo 4 personas la misma habitación.. después se plantean porque los médicos huyen de este país @hospitaldelmar